Adaptimmune Therapeutics plc (ADAP)
NASDAQ: ADAP · Real-Time Price · USD
0.0702
-0.0080 (-10.23%)
Aug 14, 2025, 11:21 AM - Market open
Adaptimmune Therapeutics Stock Forecast
ADAP's stock price has decreased by -93.24% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts that cover Adaptimmune Therapeutics stock have a consensus rating of "Hold" and an average price target of $1.02, which forecasts a 1,352.99% increase in the stock price over the next year. The lowest target is $0.46 and the highest is $1.75.
Price Target: $1.02 (+1,352.99%)
Analyst Consensus: Hold
* Price targets were last updated on Jun 26, 2025.
Analyst Ratings
The average analyst rating for Adaptimmune Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Buy | 2 | 2 | 2 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 2 | 3 | 3 |
| Sell | 0 | 0 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jul 29, 2025 |
| Mizuho | Mizuho | Buy → Hold Downgrades $1.5 → $0.5 | Buy → Hold | Downgrades | $1.5 → $0.5 | +612.25% | Jun 26, 2025 |
| Barclays | Barclays | Sell Maintains $1 → $0.46 | Sell | Maintains | $1 → $0.46 | +555.27% | May 14, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $1.5 → $1 | Hold | Maintains | $1.5 → $1 | +1,324.50% | May 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $3.5 → $3 | Strong Buy | Maintains | $3.5 → $3 | +4,173.50% | Apr 1, 2025 |
Financial Forecast
Revenue This Year
47.87M
from 178.03M
Decreased by -73.11%
Revenue Next Year
66.41M
from 47.87M
Increased by 38.72%
EPS This Year
-0.47
from -0.30
EPS Next Year
-0.25
from -0.47
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 56.8M | 89.3M | 159.7M | ||
| Avg | 47.9M | 66.4M | 124.0M | ||
| Low | 32.0M | 36.0M | 54.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -68.1% | 86.4% | 140.5% | ||
| Avg | -73.1% | 38.7% | 86.8% | ||
| Low | -82.0% | -24.9% | -17.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.42 | -0.05 | -0.16 |
| Avg | -0.47 | -0.25 | -0.28 |
| Low | -0.49 | -0.48 | -0.38 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.